期刊
NATURE REVIEWS DRUG DISCOVERY
卷 14, 期 2, 页码 130-146出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd4504
关键词
-
资金
- UK National Health Service
- Institute of Cancer Research NIHR Biomedical Research Centre
- US National Institutes of Health/National Cancer Institute (NIH/NCI) [CA129134, CA188650]
- NIH/NCI [CA163863]
- Cancer Research UK [16642] Funding Source: researchfish
Cancer represents a pathological manifestation of uncontrolled cell division; therefore, it has long been anticipated that our understanding of the basic principles of cell cycle control would result in effective cancer therapies. In particular, cyclin-dependent kinases (CDKs) that promote transition through the cell cycle were expected to be key therapeutic targets because many tumorigenic events ultimately drive proliferation by impinging on CDK4 or CDK6 complexes in the Cl phase of the cell cycle. Moreover, perturbations in chromosomal stability and aspects of S phase and G2/M control mediated by CDK2 and CDK1 are pivotal tumorigenic events. Translating this knowledge into successful clinical development of CDK inhibitors has historically been challenging, and numerous CDK inhibitors have demonstrated disappointing results in clinical trials. Here, we review the biology of CDKs, the rationale for therapeutically targeting discrete kinase complexes and historical clinical results of CDK inhibitors. We also discuss how CDK inhibitors with high selectivity (particularly for both CDK4 and CDK6), in combination with patient stratification, have resulted in more substantial clinical activity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据